Almi Invest backs Peptonic

Almi will convert its existing loans in the company into shares and an equity stake in the business.

The company plans to start selling its new product, Vagitocin, on the British and Baltic markets within the framework of the Name Patient programme. The global market is estimated to be worth between SEK 4-10bn.

Almi conducts investments from early-stage to the expansion phase. To date, the firm has invested SEK 1bn in 350 growth companies across all sectors. Almi recently invested in Gothenburg-based Avalanche Biotech and Karlstad-based CamCoil.

Company
Based in Växjö, Peptonic has developed a new vaginal gel with oxytocin as an active substance instead of the estrogen hormone, which comes with side effects such as increased risk of cancer and blood clots.

The products are based on professor Kerstin Uvnäs Moberg's research into the body's anti-stress system and the characteristics of oxytocins.

People
Allan Asp is an investment manager at Almi. Dan Markusson is the CEO of Peptonic Medical.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Early-stage
• Healthcare
• Now researching
• Sweden
• Almi Invest